Testicular cancer - new approaches in surgery and systemic treatment

**Location:** Room Paris, North Hall (Level 1)

**Chairs:**
- M. Jewett, Toronto (CA)
- D.L. Nicol, London (GB)
- N. Nicolai, Milan (IT)

**Aims and objectives of this session**
This session will update the audience with new indications and outcome results from surgical approaches together with new systemic treatment options for patients with advanced germ cell cancer. In addition, quality of care issues will be discussed based on large registries.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (+) are 3 minutes in length, followed by 3 minutes for discussion.

---

**1084**

**Non-guideline concordant treatment of testicular cancer**

*By:* Paffenholz P., Pfister D., Heidenreich A.

*Institutes:* University Hospital Cologne, Dept. of Urology, Cologne, Germany

---

**1085**

**Testicular cancer in patients with learning disabilities in England from 2001-2015: A national cohort study**


*Institutes:* University of Birmingham, Medical School, Birmingham, United Kingdom, St George's University Hospitals NHS Foundation Trust, Dept. of Urological Oncology, London, United Kingdom, University of Warwick, Cancer Research Unit, Coventry, United Kingdom, University Hospitals Birmingham NHS Foundation Trust, Dept. of Oncology, Birmingham, United Kingdom, University Hospitals Birmingham NHS Foundation Trust, Dept. of Informatics, Birmingham, United Kingdom, University of Leeds, Leeds Institute of Cancer & Pathology, Leeds, United Kingdom, University of Birmingham, School of Cancer Sciences, Birmingham, United Kingdom

---

**1086**

**Reliability of frozen section examination in a large cohort of testicular masses: What did we learn?**

*By:* Vartolomei M., Matei D., Renne G., Tringali V., Ferro M., Bianchi R., Russo A., Cozzi G., De Cobelli O.

*Institutes:* University of Medicine and Pharmacy, Targu Mures, Romania and European Institute of Oncology, Dept. of Cell and Molecular Biology and Dept. of Urology, Milan, Italy, European Institute of Oncology, Dept. of Cell and Molecular Biology and Dept. of Urology, Milan, Italy, European Institute of Oncology, Dept. of Pathology, Milan, Italy, European Institute of Oncology and University of Milan, Dept. of Urology, Milan, Italy

---

**1087**

**Diagnostic value of frozen section examination (FSE) during inguinal exploration in patients with inconclusive testicular lesions**

*By:* Fankhauser C., Beyer J., Roth L., Sulser T., Bode K.-P., Moch H., Hermanns T.

*Institutes:* University Hospital Zurich, University of Zurich, Dept. of Urology, Zurich, Switzerland, University Hospital Zurich, University of Zurich, Dept. of Oncology, Zurich, Switzerland, University Hospital Zurich, University of Zurich, Dept. of Pathology and Molecular Pathology, Zurich, Switzerland

---

**1088**

**Safety of testicular prosthesis insertion at the time of radical orchiectomy for testis cancer in patients undergoing adjuvant therapies**

*By:* Musi G., Cozzi G., Bianchi R., Mistretta F., Tringali V., Jereczeck B., Nolé F., De
Laparoscopic retroperitoneal lymph-node dissection (L-RPLND) is not only a staging procedure in stage I non-seminomatous germ-cell testicular tumors (NSGCTT): Mature data from a referral centre


Institutes: Fondazione Ircss Istituto Nazionale Tumori, Dept. of Urology, Milan, Italy; Mox-Politecnico Di Milano, Dept. of Mathematics, Milan, Italy; Fondazione Ircss Istituto Nazionale Tumori, Dept. of Medical Oncology, Milan, Italy; Fondazione Ircss Istituto Nazionale Tumori, Dept. of Pathology, Milan, Italy; Fondazione Ircss Istituto Nazionale Tumori, Emeritus, Milan, Italy

Primary retroperitoneal lymph node dissection (RPLND) in Stage II A/B seminoma patients without adjuvant treatment: A phase II trial (PRIMETEST)

By: Lusch A., Gerbaulet L., Winter C., Albers P.

Institutes: Düsseldorf University, Dept. of Urology, Düsseldorf, Germany

Surgical resection of residual tumours after adjuvant chemotherapy of germ cell (GC) tumour

By: Gonzalez F., Bossavy J-P., Otal P., Quinty–Rant M-L., Roumiguied M., Chevreau C., Malavaud B.

Institutes: Chu Toulouse Rangueil, Dept. of Vascular Surgery, Toulouse, France; Chu Toulouse Rangueil, Dept. of Radiology, Toulouse, France; Institut Universitaire Du Cancer, Dept. of Pathology, Toulouse, France; Institut Universitaire Du Cancer, Dept. of Urology, Toulouse, France; Institut Universitaire Du Cancer, Dept. of Medical Oncology, Toulouse, France

Complications and adjunctive surgical procedures in post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND) to define a tertial referral center

By: Lusch A., Gerbaulet L., Winter C., Albers P.

Institutes: Düsseldorf University, Dept. of Urology, Düsseldorf, Germany

Bone metastases in germ cell tumors: Surgical management and outcomes

By: Nini A., Konieczny M., Winter C., Lusch A., Krauspe R., Albers P.

Institutes: IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy; University Hospital Düsseldorf, Heinrich-Heine University Medical Faculty, Dept. of Orthopedic Surgery, Düsseldorf, Germany; University Hospital Düsseldorf, Heinrich-Heine University Medical Faculty, Dept. of Urology, Düsseldorf, Germany

Retinal toxicity after cisplatin-based chemotherapy in patients with testicular cancer


Institutes: University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany; Albertinen Hospital, Dept. of Urology, Hamburg, Germany; Bundeswehr Medical Center Hamburg, Dept. of Urology, Hamburg, Germany; University Medical Center Hamburg-Eppendorf, Dept. of Ophthalmology, Hamburg, Germany; University Medical Center Hamburg-Eppendorf, Dept. of Medical Oncology, Hamburg, Germany

The features and management of late relapse of non–seminomatous germ cell tumours

By: Jay A., Aldiwan M., Wijayarathna S., Huddart R., Mayer E., Nicol D.

Institutes: Royal Marsden Hospital, Dept. of Urology, Chelsea, United Kingdom

Incidence of secondary malignancies (SM) in patients (pts) with germ cell tumors (GCT) who received high-dose chemotherapy (HDCT): A retrospective study from the European Society for Blood and Marrow Transplantation (EBMT) database
Pazopanib (PZP) in germ cell tumors (GCT) after chemotherapy (CT) failure: Final results of the open label, single-group, phase 2 Pazotest trial

By: Necchi A.¹, Lo Vullo S.², Giannatempo P.³, Raggi D.¹, Calareso G.³, Togliardi E.⁴, Crippa F.⁵, Pennati M.⁶, Zaffaroni N.⁶, Perrone F.³, Colecchia M.⁷, Nicolai N.⁸, Mariani L.², Salvioni R.⁸

Institutes: Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Medical Oncology, Milan, Italy, ²Fondazione IRCCS Policlinico San Matteo, Dept. of Medical Oncology, Pavia, Italy, ³EBMT, EBMT Study Offices, Paris, France, ⁴Fondazione IRCCS Istituto Nazionale Dei Tumori, Dept. of Medical Oncology, Milan, Italy, ⁵Hospital of Ravenna, Dept. of Hematology, Ravenna, Italy

17:06 - 17:15

Final comments

N. Nicolai, Milan (IT)